Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Phase 2 Study to Evaluate the Efficacy and the Safety of OSE-127 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Previous Treatment(s)

NCT04882007 is registered in ClinicalTrials.gov with OSE Immunotherapeutics as lead sponsor.

NCT NCT04882007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04882007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Phase 2 Study to Evaluate the Efficacy and the Safety of OSE-127 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Previous Treatment(s)
Lead sponsor
OSE Immunotherapeutics
Phase
Phase 2
Overall status
Completed
Start date
October 2, 2020
Completion date
January 28, 2025
Enrollment
136 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis